MVP: systolic displacement of one or both leaflets ≥2 mm above the annular plane in a long-axis view (EHRA 2022). Use the parasternal long axis, not the apical 4-chamber view (Moss & Adams). The apical 4-chamber view cuts the saddle-shaped annulus at its low points and over-calls prolapse; the parasternal long axis cuts its high points (Moss & Adams, textbook). Loeys 2010 also allows apical long-axis 3- and 2-chamber views and sets no special criteria in Marfan syndrome. EHRA 2022 names two aetiologies: myxomatous MVP (Barlow’s disease: excess tissue, thick and long chordae, annular dilation) and fibroelastic deficiency (thin chordae with a high chance of rupture), the commoner form. Examination: midsystolic click(s) then a late systolic murmur; standing moves the click toward S1, squatting toward S2.
Unexplained syncope or NSVT: CMR (EHRA 2022, “should”); see the table below for monitoring. No pediatric guideline covers MVP or MAD; the statements below are general.
24-h Holter: EHRA 2022 says all patients with MVP (“should”); Kim 2025 says asymptomatic athletes with no high-risk feature need no further evaluation. The sources differ.
| Feature | Listed by |
|---|---|
| EHRA 2022 high-risk features | |
| Unexplained syncope | EHRA |
| NSVT | EHRA; ESC 2020 and Kim 2025 list documented ventricular arrhythmia |
| Sustained VT, haemodynamically tolerated | EHRA |
| EHRA 2022 phenotypic risk features | |
| T-wave inversion in the inferior leads | EHRA, Kim 2025, ESC 2020 |
| Repetitive polymorphic PVCs | EHRA |
| MAD (below) | EHRA, Kim 2025 |
| Redundant leaflets | EHRA |
| Enlarged left atrium or EF ≤50% | EHRA |
| LGE in the papillary muscles or next to the annulus | EHRA (ICD table only); ESC 2020: basal inferolateral fibrosis |
| Palpitations | EHRA (CMR table only) |
| Other lists only | |
| Prolonged QT | Kim 2025, ESC 2020 |
| Family history of sudden cardiac death | Kim 2025, ESC 2020 |
| Bileaflet prolapse | ESC 2020 |
| Severe MR or LV dysfunction | Kim 2025, ESC 2020 |
| Frequent PVCs with RBBB morphology | Kim 2025 |
| Strength | Recommendation | Source |
|---|---|---|
| Should | History (syncope, family history of sudden cardiac death), examination, 12-lead ECG, echo, 24-h Holter in every patient with MVP | EHRA text, Tables 4–6 |
| Should | CMR in unexplained syncope and/or NSVT | EHRA Table 8 |
| Should | AMVP: exercise test for adrenergic arrhythmia | EHRA Table 9 |
| May | AMVP with ≥1 phenotypic feature: CMR | EHRA Table 8 |
| May | Implantable loop recorder: unexplained syncope with non-revealing monitoring; AMVP with high-risk features and negative CMR; AMVP with ≥1 phenotypic feature and LGE | EHRA Table 6 |
| No class | Athletes: no high-risk feature, no further evaluation and may compete; high-risk feature, exercise test, ambulatory monitoring and CMR; arrhythmic MVP, expert assessment and ICD risk stratification | Kim 2025 Table 7 |
| Should | ICD after VF or poorly tolerated VT with no reversible cause | EHRA Table 11 |
| May | ICD: AMVP with unexplained syncope and sustained VT or NSVT likely from the mitral apparatus; AMVP with 1 high-risk and ≥2 phenotypic features | EHRA Table 11 |
| Should | PVC ablation if frequent PVCs with symptoms or reduced LV function, in an experienced centre | EHRA Table 12 |
| Stage | Echo | Next |
|---|---|---|
| No or mild MR | Child, asymptomatic: every 2–5 y (Moss & Adams, textbook). Adult, mild: every 3–5 y | Reassure; encourage exercise (Moss & Adams) |
| Moderate MR | Adult: every 1–2 y. Child: more often than 2–5 y (Moss & Adams) | Follow |
| Severe, asymptomatic, LVEF >60% and LVESD <40 mm (C1) | Every 6–12 mo; more often if the LV is dilating | Repair reasonable at a valve centre if >95% likely durable and mortality <1% (class IIa); surgery may be considered if LV size rises or EF falls on ≥3 studies (class IIb) |
| Severe, asymptomatic, LVEF ≤60% and/or LVESD ≥40 mm (C2) | – | Surgery (class I) |
| Severe, symptomatic (D) | – | Intervention whatever the LV function (class I) |
| Class | Recommendation | LOE |
|---|---|---|
| I | Symptomatic severe MR (D): mitral intervention irrespective of LV systolic function | B-NR |
| I | Asymptomatic severe MR with LVEF ≤60% or LVESD ≥40 mm (C2): surgery | B-NR |
| I | Degenerative MR: repair rather than replacement when a successful, durable repair is possible | B-NR |
| IIa | Asymptomatic severe MR, LVEF ≥60% and LVESD ≤40 mm (C1): repair if >95% likely durable without residual MR and expected mortality <1%, at a Primary or Comprehensive Valve Center | B-NR |
| IIb | C1 (LVEF >60% and LVESD <40 mm) with progressive LV enlargement or falling EF on ≥3 studies: surgery may be considered | C-LD |
| III: Harm | Disease limited to less than half the posterior leaflet: no replacement unless repair was attempted at a Primary or Comprehensive Valve Center and failed | B-NR |
| III: No benefit | Vasodilators in asymptomatic primary MR with normal LV function and normal blood pressure | B-NR |
ACC/AHA 2020 prints C1 as LVEF ≥60% and LVESD ≤40 mm in one recommendation and >60% and <40 mm in the next, in Table 17 and in Figure 8. Severe MR: vena contracta ≥0.7 cm, regurgitant volume ≥60 mL, regurgitant fraction ≥50%, ERO ≥0.40 cm² (Figure 8). Moss & Adams: anterior-leaflet repair carries a higher reoperation risk than posterior; repair in experienced centres. The 2025 ESC/EACTS recommendations are not shown.
| Population | Finding |
|---|---|
| Children Marfan, <21 y, n=185 | MAD (≥2 mm) in 60%, from the neonatal period; in 90% of those with MVP; grows 0.18 mm a year but is constant indexed to height; echo and CMR agree (kappa 0.89). Outcomes not studied (Doan 2024) |
| Children Healthy controls, CMR, 14 ± 3 y, n=30 | Largest MAD 3.6 mm (Castellanos 2025) |
| Children and young adults, connective tissue disorders, CMR, 17 ± 6 y, n=254 | Height-indexed maximum systolic MAD ≥0.033 mm/cm: events 18.6% vs 2.6% below it (AUC 0.74); events were mostly deaths (Castellanos 2025) Composite of significant ventricular arrhythmia, cardiac arrest or death from any cause: 2 arrhythmias, 5 arrests, 18 deaths. Positive predictive value 19%, negative 97%. A threshold from one retrospective single-centre study, not a society criterion. The abstract gives 34 (15%) patients with an event and the results 21 (8.3%). |
| Marfan and Loeys-Dietz, echo, n=168 | MAD in 41%, at all ages; more mitral events and earlier aortic events with MAD (Chivulescu 2021) |
| Heritable thoracic aortic disease, echo | MAD commoner with SMAD3 variants; MAD >10 mm only with TGF-β pathway variants; MAD not independently linked to events (Asokan 2024) |
| Adult General population, CMR, n=2607 | Some disjunction in 76%, mostly anterior and inferior walls; inferolateral in 5%; authors call only extensive inferolateral MAD worth work-up (Zugwitz 2022) |
| Adult MVP cohorts | MAD in 20–58%; linked to arrhythmia during follow-up but not to excess death within 10 years (EHRA 2022, citing cohorts) |
| Adult Arrhythmic MVP with a loop recorder, n=60 | Severe arrhythmia 4% per person-year; longer posterolateral MAD among the predictors (Aabel 2023) |
| Adult Idiopathic VF, CMR, n=72 | Inferolateral MAD 11% vs 1% of matched controls, some without MVP (Groeneveld 2022) |
Diagnosis, arrhythmic risk features, mitral regurgitation, MAD, sports and outcome